Journals / Hacettepe Journal of Biology and Chemistry / 2022 / Cilt: 50 - Sayı: 1

ENHANCED ANTICANCER POTENCY OF GEMCITABINE IN COMBINATIONWITH PROPOFOL IN PROSTATE CANCER

Prostat Kanserinde Gemsitabin ve Propofolün Birlikte Kullanımının Antikanser Potansiyeli

Pages
1–12
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to the results obtained from the western blot analysis, the combination of these two agents was found to lead to synergistic inhibition of the PI3K/Akt/mTOR pathway.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:I n the present study, the effects of propofol which is an intravenous anesthetic on its own and simultaneously with gemcitabine were investigated on human prostate cancer brain metastasis DU145 and bone metastasis PC3 cells at both cellular and molecular levels.
📊
Key Findings & Data:In the first stage of our study, toxic doses of these agents were determined by using the CVDK-8 and lactate dehydrogenase release test.
💡
Conclusion & Impact:According to the results obtained from the western blot analysis, the combination of these two agents was found to lead to synergistic inhibition of the PI3K/Akt/mTOR pathway.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

I n the present study, the effects of propofol which is an intravenous anesthetic on its own and simultaneously with gemcitabine were investigated on human prostate cancer brain metastasis DU145 and bone metastasis PC3 cells at both cellular and molecular levels. In the first stage of our study, toxic doses of these agents were determined by using the CVDK-8 and lactate dehydrogenase release test. In the following phases, TAC and TOS analyzes were performed to determine the biochemical effects of these agents on cell lines, and also western blot analysis was used to show the inhibition of important oncogenic PI3K/AKT/mTOR pathway in cells treated with these agents. Propofol was found to increase the effectiveness of gemcitabine in both cells. When propofol and gemcitabine were administered simultaneously at high concentrations, they reduced cell viability and increased LDH activity. According to the results obtained from the western blot analysis, the combination of these two agents was found to lead to synergistic inhibition of the PI3K/Akt/mTOR pathway.

Özet

Mevcut çalışmada insan prostat kanseri beyin metastazı DU145 ve kemik metastazı PC3 hücreleri üzerine intravenöz bir anestezik olan propofolün, kemoterapötik bir ajan olan gemsitabin ile ayrı ayrı ve eş zamanlı olarak uygulanması durumunda oluşacak etkiler hem hücresel hem de moleküler düzeyde araştırıldı. Araştırmamızın ilk aşamasında hücre proliferasyon testi CVDK-8 ve laktat dehidrogenaz (LDH) salınım testi yardımıyla söz konusu ajanların toksik olan dozları belirlendi. Devam eden safhalarda ise bu ajanların hücre hatları üzerine olan biyokimyasal etkilerini tespit etmek için Toplam Antioksidan Kapasite (TAK) ve Toplam Oksidan Durumu (TOD) analizleri ve bu ajanlarla muamele edilen hücrelerdeki onkogenik proteinlerde ifade değişimlerini göstermek amacı ile de western blot analizi gerçekleştirildi. Hem DU145 hem de PC3 hücrelerinde propofolün gemsitabinin etkinliğini arttırdığı tespit edildi. Özellikle propofol ve gemsitabinin eş zamanlı olarak yüksek konsantrasyonlarda uygulandıklarında hücre canlılığını azalttığı ve LDH aktivitesini arttırdığı gözlemlendi. Western blot analizinden elde edilen sonuçlara göre, bu iki ajanın birlikte kullanımı PI3K/Akt/mTOR yolağının sinerjistik bir şekilde inhibe olmasına yol açtığı görüldü.

🔖

Cite This Article

KARATAŞ, E. A., BAYINDIRLI, K. N. (2022). ENHANCED ANTICANCER POTENCY OF GEMCITABINE IN COMBINATIONWITH PROPOFOL IN PROSTATE CANCER. Hacettepe Journal of Biology and Chemistry, Cilt: 50 - Sayı: 1, 1–12. https://ajindex.com/articles/528906

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. K. Hariharan, V. Padmanabha, Demography and disease characteristics of prostate cancer in India, Indian J. Urol., 32 (2016) 103-108
  2. C.H. Pernar, E.M. Ebot, K.M. Wilson, L.A. Mucci, The epidemiology of prostate cancer, Cold Spring Harb. Perspect. Med., 8 (2018) a030361
  3. M.C. Markowski, M.A. Carducci, Early use of chemotherapy in metastatic prostate cancer, Cancer Treat, Rev., 55 (2017) 218-224
  4. H.J. Lavery, M.R. Cooperberg, Clinically localized prostate cancer in 2017: A review of comparative effectiveness, Urol. Oncol., 35 (2017) 40-41
  5. J. Song, Y. Song, W. Guo, J. Jia, Y. Jin, A. Bai, Regulatory roles of KDR antisense oligonucleotide on the proliferation of human prostate cancer cell line PC-3, J. BUON., 19 (2014) 770-774
  6. T. Jurić, J.S. Katanić Stanković, G. Rosić, D. Selaković, J. Joksimović, D. Mišić, V. Stanković, V. Mihailović, Protective effects of Alchemilla vulgaris L. extracts against cisplatin-induced toxicological alterations in rats, South African Journal of Botany, 128 (2020) 141-151
  7. Q.H. Du, Y.B. Xu, M.Y. Zhang, P. Yun, C.Y. He, Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity, World J. Gastroenterol., 19 (2013) 5485-5492
  8. V. Fodale, M.G. D’Arrigo, S. Triolo, S. Mondello, D. La Torre, Anesthetic techniques and cancer recurrence after surgery", The Scientific World Journal, 5 (2014) 328513
  9. W. Yang, J. Cai, C. Zabkiewicz, H. Zhang, F. Ruge, W.G. Jiang, The effects of anesthetics on recurrence and metastasis of cancer, and clinical implications, World J. Oncol., 8 (2017) 63-70
  10. J. Song, Y. Shen, J. Zhang, Q. Lian, Mini profile of potential anticancer properties of propofol. PLoS One, 9 (2014) e114440
  11. T. Mammoto, M. Mukai, A. Mammoto, Y. Yamanaka, Y. Hayashi, T. Mashimo, Y. Kishi, H. Nakamura, Intravenous anesthetic, propofol inhibits invasion of cancer cells, Cancer Lett., 18 (2002) 165-170
  12. R. Melamed, S. Bar-Yosef, G. Shakhar, S. Ben-Eliyahu, Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures, Anesth. Analg. 97 (2003) 1331-1339
  13. R.A. Siddiqui, M. Zerouga, M. Wu, A. Castillo, K. Harvey, G.P Zaloga, W. Stillwell, Anticancer properties of propofoldocosahexaenoate and propofol-eicosapentaenoate on breast cancer cells, Breast Cancer Res.,7 (2005) 645-654
  14. J. Homburger, S